Transmission path:
1, sexual transmission route;
2. Close contact;
3. Indirect contact: through contact with the clothes, daily necessities and utensils of the infected person;
4. Iatrogenic infection: medical staff failed to protect themselves during treatment and nursing, leading to self-infection or transmission to patients through medical staff;
5. Mother-to-child transmission: it is the close contact between the baby and the pregnant woman through the birth canal.
Extended data:
Nine-valent HPV vaccine
Nine-valent HPV vaccine has good immunogenicity. After three doses of inoculation, the positive conversion rate of serum antibodies of related types can almost reach 100%. After vaccination 1 month, the peak geometric average titer of antibody can reach 100 times of the antibody level after natural infection, and this value will drop to 10 times in the next two months, and will remain in the platform period.
The antibody level of the vaccine can be maintained for at least 4 years. In the clinical trial of the efficacy of the nine-valent HPV vaccine, the main end points are the persistent infection of related human papillomavirus type, genital warts of related human papillomavirus type, cervical intraepithelial neoplasia (CIN), external genital or vaginal intraepithelial neoplasia (VIN or VaIN). Clinical trials show that,
Vaccination with nine-valent HPV vaccine can produce good protective effect, which can effectively reduce the persistent infection and precancerous lesions of human papillomavirus in cervix, vagina and external genitalia, and the protective effect can reach more than 90%. Nine-valent HPV vaccine contains human papillomavirus -6 and human papillomavirus-1 1 VLP, which has a good preventive effect on condyloma acuminatum.
Baidu encyclopedia-human papillomavirus